

**Current Report No 25**

**Receipt of the decision on granting patent protection for the temperature control invention in the territory of Republic of Poland.**

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wrocław, Poland, hereby reports that today the Republic of Poland Patent Office has positively opiated and wills to grant the Company a patent protection for an invention entitled "A set for contactless temperature control, a method of generating electromagnetic radiation wavefronts and the use of the set to generate profiles of temperature fields". A condition for the patent protection execution is payment the required official fees by the Issuer, for which the Management Board of Genomtec S.A. has agreed.

The invention covers the key technical solutions related to the proprietary contactless heating and temperature detection system utilized in Issuer’s POCT platform, Genomtec® ID. It should be stressed that the invention has a universal application - it can be also used in other devices and across various industrial segments.

The Issuer informs that this is the third patent granted by the Republic of Poland Patent Office and the fifth patent secured by the Company. The Issuer is pending over twenty patent applications globally.

The Issuer's Management Board decided that the acknowledgement of the above patent is a confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual property and designs. Properly secured intellectual property and designs may constitute the Issuer's competitive advantage, allowing safer commercialization under condition that full protection is ensured on selected markets.

In the opinion of the Management Board, a high degree of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial contracts with selected partners in the scope of implementing the commercialization strategy. Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. The POCT diagnostics represented by the Genomtec® ID platform is the key area of the Issuer's activities.



For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.